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both T and B cells in the recipient, although one of them (grade III
acute GvHD pt) had received anti-lymphocyte globulin for acute
GvHD treatment. Our experience supports the results obtained
with the same regime reported by the Nottingham team. The
regime is well tolerated with sustained engraftment, acceptable
toxicity, relapse risk and TRM.
77
FLUDARABIN AND BUSULFAN AS A CONDITIONING REGIMEN FOR
ALLOGENEIC PERIPHERAL BLOOD STEM CELLS TRANSPLANTATION IN
LEUKEMIC PATIENTS
Ghavamzadeh, A., Iravani, M., Evazi, M., Shamshiri, A., Mousavi,
A., Bahar, B., Gholibeikian, S., Chardoli, B., Jahani, M. Hematology-
Oncology & BMT Research Center, Tehran, Islamic Republic of Iran.
We evaluated Fludarabin (40 mg/m2 on days -6 to -2) and
Busulfan (4 mg/kg/day on days -5 to -2) as a new conditioning
regimen for allogeneic peripheral blood stem cells transplantation
in standard-risk leukemic patients. Enrolled were 29 reportable
patients (9 ALL, 12 AML and 8 CML; F  13 M  16) from 52
transplanted patients with matched related donor. The median
patient age was 29 (range, 15-42). Cyclosporine was used as a
prophylactic agent for GVHD (3mg/kg IV till 4, 10 mg/kg oral
from day 5). The median follow-up was 123 days (range, 77-217
days). About 89.3% and 27.6% of the patients developed mucositis
(min  3, max  15) and hepatic toxicity (min  7, max  46)
respectively which resolved with conservative therapy. There was
no cardiac toxicity (except one patient with mild pericardial effu-
sion). The median of highest serum creatinin level during hospi-
talization and synchronous cyclosporine level were 1.6 mg/dl
(range, 1.1-3.6; 28.6% with Cr  2) and 275 ng/ml (range, 9-814).
One patient experienced hemorrhagic cystitis (infection was ruled
out). 17.2% experienced moderate to severe headache. 34.5% and
10% of the patients showed grade 1, 2 and grade 3 Acute GVHD
(there was no grade 4 Acute GVHD). Two ALL patients relapsed
on days95 and100 and one died (unrelated to regimen). In day
38, 92.3% of the patients had more than 90% whole blood
engraftment (with STR-PCR technique; median, 100%; range,
75-100).
It could be beneﬁcial to use Fludarabin versus Cyclophospha-
mide in standard conditioning regimen for leukemic patients be-
cause of reduced toxicity, low incidence of acute GVHD and
facilitated donor engraftment.
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CORRELATION OF PRE-HEMATOPOIETIC CELL TRANSPLANT (HCT)
PRO-INFLAMMATORY CYTOKINES IN BRONCHIOALVEOLAR LAVAGE
(BAL) FLUID WITH PULMONARY COMPLICATIONS FOLLOWING HCT IN
PATIENTS WITH INHERITED METABOLIC STORAGE DISORDERS
(IMSDS)
Kharbanda, S., Peters, C., Blazar, B.R., Milla, C.E., Haddad, I.Y.,
Cornﬁeld, D.N., Abel, S.L., Steiner, M., Grewal, S.S., Ramsay,
N.K.C., Panoskaltsis-Mortari, A., Baker, S. University of Minnesota,
Minneapolis, MN.
Introduction: HCT is recommended in selected patients with
inherited lysosomal and peroxisomal storage disorders including
the mucopolysaccharidoses (Hurler and Maroteaux-Lamy syn-
drome) and the leukodystrophies (adrenoleukodytsrophy [ALD],
globoid cell leukodystrophy [GLD], metachromatic leukodystro-
phy [MLD]). However, patients with IMSDs undergoing HCT are
at a higher risk of life threatening pulmonary complications such as
diffuse alveolar hemorrhage (DAH) and idiopathic pneumonia
syndrome (IPS). The etiology and risk factors for these complica-
tions are unknown. We obtained BAL ﬂuid from IMSD patients
prior to transplant and analyzed it for the levels of various pro-
inﬂammatory cytokines in order to investigate their correlation
with the development of subsequent pulmonary complications.
Methods: Between August 1999 and March 2003, 60 BAL speci-
mens were obtained from 48 IMSD patients pre-HCT (Hurler
-21, ALD-16, MLD-6, Maroteaux-Lamy-2, GLD-1, Mucolipido-
sis II-1, and -mannosidosis-1). BAL ﬂuid was analyzed for various
pro-inﬂammatory cytokines including IL-1, TNF-, IFN-	,
IL-2, IL-6, as well as chemokines including Migration Inhibitory
Factor (MIP-1) and Monocyte Chemotactic Protein (MCP). Re-
sults: In this series, the overall incidence of pulmonary complica-
tions was 54% (26/48), this included 25% (12/48) infectious com-
plications and 29% (14/48) non-infectious complications (mainly
DAH and IPS)). Evaluable pre-HCT BAL cytokine data was avail-
able on 35 patients. These included 5 patients in the infectious, 8
in the non-infectious and 22 in the no complications groups re-
spectively. There were trends towards higher levels of pre-HCT
IL-1 and IL-6 in patients who subsequently developed non-
infectious complications(P  NS, however) Conclusions: Our
study conﬁrms a high incidence of pulmonary complications in the
early post transplant period in patients with IMSDs. Patients with
mucopolysacchridoses are at a higher risk of developing non-
infectious complications like DAH as compared to patients with
other IMSDs. In this study sample of 48 patients, the levels of
pro-inﬂammatory cytokines were not found to be correlated with
this increased risk; however, there were deﬁnite trends towards
higher levels of IL-1 and IL-6 in the BAL ﬂuids; this may be
attributable to the small numbers of patients in the study. Further
studies are needed to conﬁrm the role of pro-inﬂammatory cyto-
kines in the pathogenesis of pulmonary complications in patients
with IMSDs.
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GRAFT-VERSUS-LYMPHOMA EFFECT YIELDS HIGH PERCENTAGE OF
DURABLE COMPLETE REMISSION IN HIGH-RISK PATIENTS FOLLOW-
ING MINI-TRANSPLANTATION WITH MAP (MITOXANTRONE, ARA-C,
AND PENTOSTATIN) REGIMEN
Liu, D., Seiter, K., Chiao, J.W., Qureshi, A., Ahmed, T. New York
Medical College and Arlin Cancer Institiute, Valhalla, NY.
We have developed a novel Non-myeloablative Stem Cell Trans-
plantation (NST) conditioning regimen (MAP regimen) using Mi-
toxantrone (40mg/m2 day-6), AraC (2 gm/m2 on day -6, -5, and
-4), and Pentostatin (5 mg/m2 on day -6 and -5, 3 mg/m2 on day
-4) for patients with hematological malignancies. Equine ATG at
15 mg/kg/day x 4 (day -5 to -2) is added for unrelated and mis-
matched transplantation. 18 patients (15 related, 4 unrelated) with
lymphoma are evaluable. Among them were 13 NHL, 5 HD. 14/18
patients had failed prior autologous stem cell transplantation
(Auto-SCT). The rest were either in advanced relapse or had poor
prognostic factors.
Median time to ANC  500 was 12 days, and to Platelets  20
was 11 days. Full donor Chimerism is achieved at 3 months. 10 pts
received Donor Leukocyte Infusion of 1 to 7 doses. 4 of the 10
patients had remarkable disease response after DLI (2 converted to
CR, 1 PR going into CR, 1 stable). 10/18 pts had acute GVHD
(grade II-IV), 4 of them developed GVHD after DLI. Day 100
mortality is 5% (1/18). With a median follow-up of 28 months
(1-38), the median duration of overall survival (OS) for these
high-risk patients has not been reached. 1 year OS is 64%, 2 year
OS is 52%. For the 14 pts who failed prior Auto-SCT, 1 year OS
is 69%, 2 year OS is 52%. These data are highly suggestive of
graft-vs-lymphoma effect. Therefore, mini-allogeneic transplanta-
tion after MAP is a favorable option for lymphoma patients, par-
ticularly for those who failed prior Auto-SCT.
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TID COMPARED TO BID MYCOPHENOLATE MOFETIL (MMF) IMPROVES
DONOR CHIMERISM AND ENGRAFTMENT RATES WITHOUT INCREAS-
ING POSTGRAFTING TOXICITIES AFTER UNRELATED PERIPHERAL
BLOOD STEM CELL (PBSC) TRANSPLANTATION (HCT) WITH NONMY-
ELOABLATIVE CONDITIONING
Maris, M.B.1,2, Sandmaier, B.M.1,2, Storer, B.1,2, Stuart, M.3, Agura,
E.4, Hegenbart, U.5, Pulsipher, M.6, Maziarz, R.T.7, Bruno, B.8,
McSweeney, P.9, Maloney, D.1,2, Niederwieser, D.5, Blume, K.3, Storb,
R.1,2 1. Fred Hutchinson Cancer Research Center; 2. University of
Washington; 3. Stanford University; 4. Baylor University, Dallas; 5.
University of Leipzig, Germany; 6. Oregon Health and Sciences Uni-
versity; 7. University of Turin, Italy; 8. University of Colorado.
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